Literature DB >> 35273432

Regular Risk Assessment in Pulmonary Arterial Hypertension - A Whistleblower for Hidden Disease Progression.

Shu-Hao Wu1,2, Yih-Jer Wu1,2.   

Abstract

Despite developments in the treatment of pulmonary arterial hypertension, timely treatment is seldom achieved, and hidden progression is not uncommonly disguised as a seemingly "stable" condition. Appropriate risk assessment tools facilitate goal-oriented treatment strategies. This article aimed to review the development of these risk assessment tools including early assessment equations/scores, European guidelines-based risk assessment scores, and tools derived from the United States nationwide registry. A stepwise and regular approach with these assessment tools in clinical practice is highly recommended for timely treatment escalation to stop disease progression early. In this review, a practical and recommended algorithm of these assessment tools is also provided.

Entities:  

Keywords:  Guidelines; Pulmonary arterial hypertension; REVEAL; Risk assessment

Year:  2022        PMID: 35273432      PMCID: PMC8888324          DOI: 10.6515/ACS.202203_38(2).20211005A

Source DB:  PubMed          Journal:  Acta Cardiol Sin        ISSN: 1011-6842            Impact factor:   2.672


  63 in total

1.  Validation of the pulmonary hypertension connection equation for survival prediction in pulmonary arterial hypertension.

Authors:  Thenappan Thenappan; Cherylanne Glassner; Mardi Gomberg-Maitland
Journal:  Chest       Date:  2011-09-01       Impact factor: 9.410

2.  The REVEAL Registry risk score calculator in patients newly diagnosed with pulmonary arterial hypertension.

Authors:  Raymond L Benza; Mardi Gomberg-Maitland; Dave P Miller; Adaani Frost; Robert P Frantz; Aimee J Foreman; David B Badesch; Michael D McGoon
Journal:  Chest       Date:  2011-06-16       Impact factor: 9.410

3.  Performance of the REVEAL pulmonary arterial hypertension prediction model using non-invasive and routinely measured parameters.

Authors:  Rebecca Cogswell; Marc Pritzker; Teresa De Marco
Journal:  J Heart Lung Transplant       Date:  2013-12-26       Impact factor: 10.247

4.  Usefulness of Adding Echocardiography of the Right Heart to Risk-Assessment Scores in Prostanoid-Treated Pulmonary Arterial Hypertension.

Authors:  Roberto Badagliacca; Silvia Papa; Giovanna Manzi; Cristiano Miotti; Federico Luongo; Susanna Sciomer; Nadia Cedrone; Francesco Fedele; Robert Naeije; Carmine Dario Vizza
Journal:  JACC Cardiovasc Imaging       Date:  2020-06-17

5.  REVEAL risk scores applied to riociguat-treated patients in PATENT-2: Impact of changes in risk score on survival.

Authors:  Raymond L Benza; Harrison W Farber; Adaani Frost; Hossein-Ardeschir Ghofrani; Miguel A Gómez-Sánchez; David Langleben; Stephan Rosenkranz; Dennis Busse; Christian Meier; Sylvia Nikkho; Marius M Hoeper
Journal:  J Heart Lung Transplant       Date:  2017-11-11       Impact factor: 10.247

6.  Riociguat for the treatment of pulmonary arterial hypertension.

Authors:  Hossein-Ardeschir Ghofrani; Nazzareno Galiè; Friedrich Grimminger; Ekkehard Grünig; Marc Humbert; Zhi-Cheng Jing; Anne M Keogh; David Langleben; Michael Ochan Kilama; Arno Fritsch; Dieter Neuser; Lewis J Rubin
Journal:  N Engl J Med       Date:  2013-07-25       Impact factor: 91.245

7.  Predicting survival in pulmonary arterial hypertension: insights from the Registry to Evaluate Early and Long-Term Pulmonary Arterial Hypertension Disease Management (REVEAL).

Authors:  Raymond L Benza; Dave P Miller; Mardi Gomberg-Maitland; Robert P Frantz; Aimee J Foreman; Christopher S Coffey; Adaani Frost; Robyn J Barst; David B Badesch; C Gregory Elliott; Theodore G Liou; Michael D McGoon
Journal:  Circulation       Date:  2010-06-28       Impact factor: 29.690

8.  2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT).

Authors:  Nazzareno Galiè; Marc Humbert; Jean-Luc Vachiery; Simon Gibbs; Irene Lang; Adam Torbicki; Gérald Simonneau; Andrew Peacock; Anton Vonk Noordegraaf; Maurice Beghetti; Ardeschir Ghofrani; Miguel Angel Gomez Sanchez; Georg Hansmann; Walter Klepetko; Patrizio Lancellotti; Marco Matucci; Theresa McDonagh; Luc A Pierard; Pedro T Trindade; Maurizio Zompatori; Marius Hoeper
Journal:  Eur Heart J       Date:  2015-08-29       Impact factor: 29.983

9.  Guideline implementation and early risk assessment in pulmonary arterial hypertension associated with congenital heart disease: A retrospective cohort study.

Authors:  Xiaoxian Deng; Bowen Jin; Shanshan Li; Yaping Li; Hongmei Zhou; Yang Wu; Menghuan Yan; Yuanping Hu; Qiu Qiu; Gangcheng Zhang; Xuan Zheng
Journal:  Clin Respir J       Date:  2019-08-29       Impact factor: 2.570

10.  Comparison of the capability of risk stratification evaluation between two- and three-dimensional speckle-tracking strain in pre-capillary pulmonary hypertension.

Authors:  Bing-Yang Liu; Wei-Chun Wu; Qi-Xian Zeng; Zhi-Hong Liu; Li-Li Niu; Yue Tian; Qin Luo; Zhi-Hui Zhao; Rui-Lin Quan; Jing-Ru Lin; Hao Wang; Jian-Guo He; Chang-Ming Xiong
Journal:  Pulm Circ       Date:  2019-12-27       Impact factor: 3.017

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.